Yihong Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yihong Sun has a total of 257 co-authors. Here are the top co-authors by number of shared publications:
Zhe Wang
20 shared publicationsYinong Chen
Peking University China-Japan Friendship School of Clinical Medicine, China
10 shared publicationsQing Li
Peking University Health Science Center China‐Japan Friendship Hospital Beijing China
9 shared publicationsSiqi Jiao
Peking University Health Science Center China‐Japan Friendship Hospital Beijing China
9 shared publicationsLongyang Zhu
Peking University Health Science Center China‐Japan Friendship Hospital Beijing China
8 shared publicationsShuwen Zheng
8 shared publications
Latest Publications
- Open Access
- 23 July 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (9) , 2111-2122
Non-ACS Presentation in Takotsubo Syndrome
- 23 July 2026
- Published by Elsevier in JACC: Asia
- Vol. 6 (9) , 2111-2122
Open AccessNon-ACS Presentation in Takotsubo Syndrome
- Top Cited Papers
- 13 July 2026
- Published by Springer Nature in Nature Reviews Cardiology
World Heart Federation Roadmap on cardiac rehabilitation: a pathway to lifelong cardiovascular health.
With an ageing population and the persistence of unhealthy lifestyle behaviours, health-care systems are challenged by a growing number of individuals living longer with cardiovascular disease and its sequelae. The evolution of cardiac rehabilitation, from a group exercise-based programme to encompassing all aspects of secondary prevention, has led to the ultimate objective of achieving lifelong cardiovascular health for all. In this World Heart Federation Roadmap, we present a united and forward-looking vision to consolidate global and collaborative efforts that enhance equitable access, improve patient outcomes and ensure value-based health care. The Roadmap outlines a reframing of terminology and interconnected solutions founded on unity, person-centredness and being future-focused. The five key roadblocks and widely applicable solutions are interlinked and include having a greater emphasis on lifelong cardiovascular health, better engagement among patients and clinicians, a greater emphasis on new models of care, workforce strengthening and support for strong advocacy and policy. We present a series of practical solutions and successful international case studies. The next steps are to facilitate local and regional implementation and evaluation strategies. A shift to systems, policy and advocacy thinking is crucial for the sector, with a view to long-term investment to meet growing demands. This World Heart Federation Roadmap is endorsed by the International Council of Cardiovascular Prevention and Rehabilitation.
- 13 July 2026
- Published by Springer Nature in Nature Reviews Cardiology
Top Cited PapersWorld Heart Federation Roadmap on cardiac rehabilitation: a pathway to lifelong cardiovascular health.
With an ageing population and the persistence of unhealthy lifestyle behaviours, health-care systems are challenged by a growing number of individuals living longer with cardiovascular disease and its sequelae. The evolution of cardiac rehabilitation, from a group exercise-based programme to encompassing all aspects of secondary prevention, has led to the ultimate objective of achieving lifelong cardiovascular health for all. In this World Heart Federation Roadmap, we present a united and forward-looking vision to consolidate global and collaborative efforts that enhance equitable access, improve patient outcomes and ensure value-based health care. The Roadmap outlines a reframing of terminology and interconnected solutions founded on unity, person-centredness and being future-focused. The five key roadblocks and widely applicable solutions are interlinked and include having a greater emphasis on lifelong cardiovascular health, better engagement among patients and clinicians, a greater emphasis on new models of care, workforce strengthening and support for strong advocacy and policy. We present a series of practical solutions and successful international case studies. The next steps are to facilitate local and regional implementation and evaluation strategies. A shift to systems, policy and advocacy thinking is crucial for the sector, with a view to long-term investment to meet growing demands. This World Heart Federation Roadmap is endorsed by the International Council of Cardiovascular Prevention and Rehabilitation.
- Open Access
- 16 June 2026
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 54 (6)
Plasma soluble triggering receptor expressed on myeloid cells 2 levels and clinical outcomes in acute decompensated heart failure: A retrospective cohort study
Objective: Emerging evidence suggests a potential role for soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cardiovascular pathophysiology. However, plasma sTREM2 levels in patients with acute decompensated heart failure and their possible association with adverse clinical outcomes have not been fully characterized. Methods: In this retrospective cohort study, we enrolled patients with acute decompensated heart failure between 2020 and 2023 and defined a composite endpoint comprising all-cause mortality and heart failure–related readmission. Baseline plasma sTREM2 levels were compared across clinical categories and acute decompensated heart failure phenotypes using appropriate statistical tests. The prognostic value of sTREM2 was evaluated using Kaplan–Meier survival curves, restricted cubic splines, and Cox proportional hazards regression models. Model calibration was validated using bootstrap-corrected plots with 1000 resamples. Furthermore, time-dependent receiver operating characteristic curves, net reclassification improvement, and integrated discrimination improvement were used to assess the incremental predictive value of sTREM2 over N-terminal pro-B-type natriuretic peptide. Finally, subgroup analyses were performed to assess the robustness of the findings. Results: A total of 128 patients (median age, 75.5 years) were enrolled, with 58 (45.3%) reaching the composite endpoint during follow-up. Plasma sTREM2 levels were significantly higher in patients with acute decompensated heart failure than in healthy controls ( P < 0.001) and showed a progressive increase with worsening New York Heart Association functional class. Multivariable Cox regression analysis demonstrated that each 50 pg/mL increment in sTREM2 was independently associated with an increased risk of the composite endpoint (adjusted hazard ratio: 1.594; 95% confidence interval: 1.170–2.173) and heart failure–related readmission (adjusted hazard ratio: 1.802; 95% confidence interval: 1.310–2.480). Restricted cubic spline analysis confirmed a linear association between sTREM2 levels and clinical outcomes (all P for nonlinear > 0.05). Although adding sTREM2 to N-terminal pro-B-type natriuretic peptide did not significantly increase the area under the curve, it provided incremental predictive value for heart failure–related readmission. Subgroup analyses revealed no significant interactions (all P for interaction > 0.05). Conclusion: Our findings demonstrate that sTREM2 is a potential biomarker in acute decompensated heart failure. Elevated sTREM2 levels are independently associated with an increased risk of adverse clinical outcomes, particularly heart failure–related readmission, underscoring its potential utility in risk stratification and clinical management of acute decompensated heart failure.
- 16 June 2026
- Published by SAGE Publications in Journal of International Medical Research
- Vol. 54 (6)
Open AccessPlasma soluble triggering receptor expressed on myeloid cells 2 levels and clinical outcomes in acute decompensated heart failure: A retrospective cohort study
Objective: Emerging evidence suggests a potential role for soluble triggering receptor expressed on myeloid cells 2 (sTREM2) in cardiovascular pathophysiology. However, plasma sTREM2 levels in patients with acute decompensated heart failure and their possible association with adverse clinical outcomes have not been fully characterized. Methods: In this retrospective cohort study, we enrolled patients with acute decompensated heart failure between 2020 and 2023 and defined a composite endpoint comprising all-cause mortality and heart failure–related readmission. Baseline plasma sTREM2 levels were compared across clinical categories and acute decompensated heart failure phenotypes using appropriate statistical tests. The prognostic value of sTREM2 was evaluated using Kaplan–Meier survival curves, restricted cubic splines, and Cox proportional hazards regression models. Model calibration was validated using bootstrap-corrected plots with 1000 resamples. Furthermore, time-dependent receiver operating characteristic curves, net reclassification improvement, and integrated discrimination improvement were used to assess the incremental predictive value of sTREM2 over N-terminal pro-B-type natriuretic peptide. Finally, subgroup analyses were performed to assess the robustness of the findings. Results: A total of 128 patients (median age, 75.5 years) were enrolled, with 58 (45.3%) reaching the composite endpoint during follow-up. Plasma sTREM2 levels were significantly higher in patients with acute decompensated heart failure than in healthy controls ( P < 0.001) and showed a progressive increase with worsening New York Heart Association functional class. Multivariable Cox regression analysis demonstrated that each 50 pg/mL increment in sTREM2 was independently associated with an increased risk of the composite endpoint (adjusted hazard ratio: 1.594; 95% confidence interval: 1.170–2.173) and heart failure–related readmission (adjusted hazard ratio: 1.802; 95% confidence interval: 1.310–2.480). Restricted cubic spline analysis confirmed a linear association between sTREM2 levels and clinical outcomes (all P for nonlinear > 0.05). Although adding sTREM2 to N-terminal pro-B-type natriuretic peptide did not significantly increase the area under the curve, it provided incremental predictive value for heart failure–related readmission. Subgroup analyses revealed no significant interactions (all P for interaction > 0.05). Conclusion: Our findings demonstrate that sTREM2 is a potential biomarker in acute decompensated heart failure. Elevated sTREM2 levels are independently associated with an increased risk of adverse clinical outcomes, particularly heart failure–related readmission, underscoring its potential utility in risk stratification and clinical management of acute decompensated heart failure.
- Open Access
- 16 June 2026
- Published by Elsevier in Brain Research
- Vol. 1888, 150433
Ultra-high-field 7T MRI reveals neural abnormalities of attention networks in relation to cognitive impairment in hypertension
- 16 June 2026
- Published by Elsevier in Brain Research
- Vol. 1888, 150433
Open AccessUltra-high-field 7T MRI reveals neural abnormalities of attention networks in relation to cognitive impairment in hypertension
- Open Access
- 19 June 2025
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 19 (6) , e70060
ECG Abnormalities and Biomarkers Enable Rapid Risk Stratification in Normotensive Patients With Acute Pulmonary Embolism
Background: The patients with suspected pulmonary embolism (PE) were usually screened using electrocardiogram (ECG) and blood panel of D‐dimer, troponin, and blood gas analysis in the emergency.Objectives: This study aimed to explore a rapid risk model to predict in‐hospital adverse events for normotensive PE patients.Methods: Patients with acute PE having normal blood pressure on appearance were retrospectively enrolled at China‐Japan Friendship Hospital from January 2017 to February 2020. The in‐hospital adverse events were defined as death and clinical deterioration during hospitalization. The risk model for in‐hospital adverse events was generated by multivariate regression analysis. The discrimination ability of the model was compared with PESI, Bova, and FAST risk score, and evaluated by the receiver operating characteristic curve (ROC), net reclassification improvement (NRI), and integrated discrimination improvement index (IDI).Results: Of the 213 patients, 35 (16.4%) experienced in‐hospital adverse events,y including 15 deaths. The average age was 69 ± 19 years, and 118 (44.6%) were females. Multiple logistic regression analysis showed that independent risk factors associated with in‐hospital adverse events were low QRS voltage in ECG (OR: 5.321; 95% CI: 1.608–7.310), positive age‐adjusted D‐dimer (OR: 2.061; 95% CI: 0.622–6.836), positive troponin (OR: 3.504; 95% CI: 1.744–8.259), and PaO2/FiO2 < 300 (OR: 3.268; 95% CI: 0.978–5.260). The ROC analysis showed that the AUC of the new model (0.847, 95% CI: 0.786–0.901) was better than the PESI score (0.628, 95% CI: 0.509–0.769), the Bova score (0.701, 95% CI: 0.594–0.808), and the FAST score (0.775 95% CI: 0.690–0.859).Conclusion: ECG abnormalities and biomarkers on admission may provide a rapid and effective approach to identify patients with poor prognoses during hospitalization.
- 19 June 2025
- Published by Wiley in The Clinical Respiratory Journal
- Vol. 19 (6) , e70060
Open AccessECG Abnormalities and Biomarkers Enable Rapid Risk Stratification in Normotensive Patients With Acute Pulmonary Embolism
Background: The patients with suspected pulmonary embolism (PE) were usually screened using electrocardiogram (ECG) and blood panel of D‐dimer, troponin, and blood gas analysis in the emergency.Objectives: This study aimed to explore a rapid risk model to predict in‐hospital adverse events for normotensive PE patients.Methods: Patients with acute PE having normal blood pressure on appearance were retrospectively enrolled at China‐Japan Friendship Hospital from January 2017 to February 2020. The in‐hospital adverse events were defined as death and clinical deterioration during hospitalization. The risk model for in‐hospital adverse events was generated by multivariate regression analysis. The discrimination ability of the model was compared with PESI, Bova, and FAST risk score, and evaluated by the receiver operating characteristic curve (ROC), net reclassification improvement (NRI), and integrated discrimination improvement index (IDI).Results: Of the 213 patients, 35 (16.4%) experienced in‐hospital adverse events,y including 15 deaths. The average age was 69 ± 19 years, and 118 (44.6%) were females. Multiple logistic regression analysis showed that independent risk factors associated with in‐hospital adverse events were low QRS voltage in ECG (OR: 5.321; 95% CI: 1.608–7.310), positive age‐adjusted D‐dimer (OR: 2.061; 95% CI: 0.622–6.836), positive troponin (OR: 3.504; 95% CI: 1.744–8.259), and PaO2/FiO2 < 300 (OR: 3.268; 95% CI: 0.978–5.260). The ROC analysis showed that the AUC of the new model (0.847, 95% CI: 0.786–0.901) was better than the PESI score (0.628, 95% CI: 0.509–0.769), the Bova score (0.701, 95% CI: 0.594–0.808), and the FAST score (0.775 95% CI: 0.690–0.859).Conclusion: ECG abnormalities and biomarkers on admission may provide a rapid and effective approach to identify patients with poor prognoses during hospitalization.
- Open Access
- 1 May 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (5) , e011441
Impact of In-Hospital Quality of Care Improvement Initiative on Secondary Prevention of Acute Coronary Syndrome in Six Months After Patient Discharge: A Large Stepped Wedge- and Cluster-Randomized Controlled Trial
BACKGROUND: Patients discharged after acute coronary syndrome experience a high risk of major adverse cardiovascular events (MACE) within the first 6 months. We examined whether a quality of care improvement initiative implemented in hospitals affects clinical preventive management and outcomes after discharge. METHODS: We used data from the third phase of the CPACS-3 study (Clinical Pathways for Acute Coronary Syndromes in China), a large stepped wedge- and cluster-randomized trial conducted from 2011 to 2015, to evaluate the effectiveness of an in-hospital quality of care improvement program on the composite score of preventive medication use and the risk of MACE in 6 months after discharge among acute coronary syndrome survivors. The intervention included establishing a quality of care improvement team, training clinical staff, implementing acute coronary syndrome clinical pathways, performance assessment and feedback, online technical support, and patient education. A total of 101 hospitals were randomized into 4 wedges, and the intervention was initiated randomly by wedge and step. Participants recruited before (control) and after (intervention) the intervention initiation were compared with generalized estimating equations, adjusting for clustering and time trend. RESULTS: A total of 23 258 patients (11 224 in the intervention group and 12 034 in the control group), with a mean age of 63.6±11.6 years and 39% women, had available follow-up data on MACE and 14 826 patients (6813 in the intervention group and 8013 in the control group) had available data on preventive medication use at 6 months were analyzed. Compared with the control period, the mean preventive medication use score during the intervention period was higher at 6 months (65.8 versus 60.4 for intervention and control periods, adjusted mean difference, 3.7 [95% CI, 0.3–7.0]), but the 6-month incidence of MACE showed no difference (5.8% versus 6.6%, adjusted odds ratio, 1.04 [95% CI, 0.83–1.29]). CONCLUSIONS: The in-hospital multifaceted quality of care improvement intervention in resource-constrained Chinese hospitals increased preventive medication use among acute coronary syndrome survivors in the 6 months after discharge, but this did not translate into a reduction in MACE. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01398228.
- 1 May 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (5) , e011441
Open AccessImpact of In-Hospital Quality of Care Improvement Initiative on Secondary Prevention of Acute Coronary Syndrome in Six Months After Patient Discharge: A Large Stepped Wedge- and Cluster-Randomized Controlled Trial
BACKGROUND: Patients discharged after acute coronary syndrome experience a high risk of major adverse cardiovascular events (MACE) within the first 6 months. We examined whether a quality of care improvement initiative implemented in hospitals affects clinical preventive management and outcomes after discharge. METHODS: We used data from the third phase of the CPACS-3 study (Clinical Pathways for Acute Coronary Syndromes in China), a large stepped wedge- and cluster-randomized trial conducted from 2011 to 2015, to evaluate the effectiveness of an in-hospital quality of care improvement program on the composite score of preventive medication use and the risk of MACE in 6 months after discharge among acute coronary syndrome survivors. The intervention included establishing a quality of care improvement team, training clinical staff, implementing acute coronary syndrome clinical pathways, performance assessment and feedback, online technical support, and patient education. A total of 101 hospitals were randomized into 4 wedges, and the intervention was initiated randomly by wedge and step. Participants recruited before (control) and after (intervention) the intervention initiation were compared with generalized estimating equations, adjusting for clustering and time trend. RESULTS: A total of 23 258 patients (11 224 in the intervention group and 12 034 in the control group), with a mean age of 63.6±11.6 years and 39% women, had available follow-up data on MACE and 14 826 patients (6813 in the intervention group and 8013 in the control group) had available data on preventive medication use at 6 months were analyzed. Compared with the control period, the mean preventive medication use score during the intervention period was higher at 6 months (65.8 versus 60.4 for intervention and control periods, adjusted mean difference, 3.7 [95% CI, 0.3–7.0]), but the 6-month incidence of MACE showed no difference (5.8% versus 6.6%, adjusted odds ratio, 1.04 [95% CI, 0.83–1.29]). CONCLUSIONS: The in-hospital multifaceted quality of care improvement intervention in resource-constrained Chinese hospitals increased preventive medication use among acute coronary syndrome survivors in the 6 months after discharge, but this did not translate into a reduction in MACE. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT01398228.
- 9 October 2024
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 40 (1) , 31-36
The management of new-onset atrial fibrillation in critical illness: an update on current therapeutic options
Purpose of review: New-onset atrial fibrillation (NOAF) is the most prevalent arrhythmia among critically ill patients, correlating with heightened morbidity and mortality rates. Current evidence for managing NOAF in this patient population is limited. Recent findings: Numerous meta-analyses have been conducted to assess the efficacy of atrial fibrillation treatments in acute settings, including rate or rhythm control strategies, anticoagulation, and intensive care interventions. The employment of β-blockers for rate control appears to confer greater benefits in critically ill patients. However, the advantage of anticoagulation remains ambiguous because of bleeding risks, which is partly attributed to the scarcity of evidence in the complex context of critical illness. Approximately one-third of patients with transient atrial fibrillation face recurrence within a year. Therefore, vigilant posthospitalization follow-up and monitoring should be considered for high-risk patients to detect atrial fibrillation recurrence. Long-term anticoagulation strategies should be tailored to individual patient profiles, weighing the risks of thromboembolism. Summary: Factors predicting atrial fibrillation recurrence include age, the burden of atrial fibrillation, and atrial size. There are significant knowledge gaps concerning NOAF in critically ill patients, highlighting the need for further research, particularly randomized clinical trials.
- 9 October 2024
- Published by Wolters Kluwer Health in Current Opinion in Cardiology
- Vol. 40 (1) , 31-36
The management of new-onset atrial fibrillation in critical illness: an update on current therapeutic options
Purpose of review: New-onset atrial fibrillation (NOAF) is the most prevalent arrhythmia among critically ill patients, correlating with heightened morbidity and mortality rates. Current evidence for managing NOAF in this patient population is limited. Recent findings: Numerous meta-analyses have been conducted to assess the efficacy of atrial fibrillation treatments in acute settings, including rate or rhythm control strategies, anticoagulation, and intensive care interventions. The employment of β-blockers for rate control appears to confer greater benefits in critically ill patients. However, the advantage of anticoagulation remains ambiguous because of bleeding risks, which is partly attributed to the scarcity of evidence in the complex context of critical illness. Approximately one-third of patients with transient atrial fibrillation face recurrence within a year. Therefore, vigilant posthospitalization follow-up and monitoring should be considered for high-risk patients to detect atrial fibrillation recurrence. Long-term anticoagulation strategies should be tailored to individual patient profiles, weighing the risks of thromboembolism. Summary: Factors predicting atrial fibrillation recurrence include age, the burden of atrial fibrillation, and atrial size. There are significant knowledge gaps concerning NOAF in critically ill patients, highlighting the need for further research, particularly randomized clinical trials.
- Open Access
- 25 June 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (7) , 1047-1054
Relationship Between Epicardial Adipose Tissue Volume and Recurrence After Ablation in Premature Ventricular Complexes
Background: Epicardial adipose tissue (EAT) is recognized as a clinical diagnostic marker for cardiometabolic disease. Thicker EAT may be associated with recurrence of ventricular tachycardia after ablation. The association between EAT volume and recurrence of premature ventricular complexes (PVC) following ablation has not been clarified. We investigated the association between EAT volume and PVC recurrence following radiofrequency catheter ablation.Methods and Results: This retrospective study included 401 patients with PVC undergoing catheter ablation with preprocedural non-contrast computed tomography between 2017 and 2022. The impact of EAT volume in predicting PVC recurrence after ablation was analyzed. The mean (±SD) age of patients was 50.2±13.3 years. Multivariable Cox analysis revealed that a large EAT volume was an independent predictor of PVC recurrence after ablation during a median follow-up of 16.3 months. Kaplan-Meier analysis showed a difference in postablation PVC recurrence between the 2 groups dichotomized around the EAT volume cut-off. The risk of recurrence increased with increasing EAT volume according to restricted cubic spline regression. Furthermore, PVC originating from epicardial locations had larger EAT volumes than those originating from the right ventricular outflow tract.Conclusions: A large EAT volume was independently associated with PVC recurrence following ablation. Patients with PVC originating from epicardial sites had large EAT volumes. EAT volume may help stratify patients according to their risk of PVC recurrence after ablation.
- 25 June 2024
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 88 (7) , 1047-1054
Open AccessRelationship Between Epicardial Adipose Tissue Volume and Recurrence After Ablation in Premature Ventricular Complexes
Background: Epicardial adipose tissue (EAT) is recognized as a clinical diagnostic marker for cardiometabolic disease. Thicker EAT may be associated with recurrence of ventricular tachycardia after ablation. The association between EAT volume and recurrence of premature ventricular complexes (PVC) following ablation has not been clarified. We investigated the association between EAT volume and PVC recurrence following radiofrequency catheter ablation.Methods and Results: This retrospective study included 401 patients with PVC undergoing catheter ablation with preprocedural non-contrast computed tomography between 2017 and 2022. The impact of EAT volume in predicting PVC recurrence after ablation was analyzed. The mean (±SD) age of patients was 50.2±13.3 years. Multivariable Cox analysis revealed that a large EAT volume was an independent predictor of PVC recurrence after ablation during a median follow-up of 16.3 months. Kaplan-Meier analysis showed a difference in postablation PVC recurrence between the 2 groups dichotomized around the EAT volume cut-off. The risk of recurrence increased with increasing EAT volume according to restricted cubic spline regression. Furthermore, PVC originating from epicardial locations had larger EAT volumes than those originating from the right ventricular outflow tract.Conclusions: A large EAT volume was independently associated with PVC recurrence following ablation. Patients with PVC originating from epicardial sites had large EAT volumes. EAT volume may help stratify patients according to their risk of PVC recurrence after ablation.